Amplifica Holdings Group has raised $26 million in an oversubscribed Series B financing to advance a pipeline of injectable treatments designed to reactivate dormant hair follicles and stimulate new hair growth. Tasso Partners led the round, with participation from Eli Lilly and Company, principals of Scopia Capital Management, and other new and existing investors.
The financing will support continued clinical development of Amplifica’s pipeline candidates as the company seeks to develop alternatives to existing hair-loss treatments that are primarily intended to slow or prevent further loss.
Amplifica is taking a different approach by targeting biological signaling mechanisms involved in the hair follicle growth cycle.
The company has developed a proprietary portfolio of signaling molecules intended to activate follicle regeneration through distinct but complementary mechanisms.
Amplifica believes advancing several mechanisms in parallel could improve the probability of clinical success while creating a broader treatment platform for both men and women experiencing androgenetic alopecia.
The condition affects an estimated 50 million men and 30 million women in the U.S.
Current standard-of-care options include finasteride and minoxidil.
While widely used, Amplifica notes that these therapies can deliver only modest improvements in hair count and may present challenges involving daily adherence, tolerability, side effects, and limited applicability for some female patients.
The company sees those limitations as creating room for injectable therapies that could potentially offer a different efficacy and treatment profile.
Amplifica’s scientific approach is based on identifying and isolating signaling molecules that can stimulate follicles to resume natural hair growth.
The company is now focusing more of its resources on advancing injectable product candidates through clinical development.
The Series B follows Amplifica’s earlier work establishing its discovery platform and identifying multiple candidates with different mechanisms of action.
Management sees the new capital as sufficient to move those programs further into clinical testing and support the company’s next phase of growth.
The oversubscribed nature of the round also reflects investor interest in hair regeneration as a therapeutic category with a large addressable patient population and limited innovation relative to other areas of biopharma.
Amplifica is a privately held, clinical-stage biopharmaceutical company focused specifically on androgenetic alopecia.
Its long-term goal is to develop treatments that do more than simply preserve existing hair by directly promoting regrowth through follicle reactivation.
KEY QUOTES:
“Closing this oversubscribed round reflects strong investor conviction in the science behind our injectable approach and in the size of the opportunity it addresses.”
“This capital allows us to accelerate our mission to deliver next-generation products to patients confronting the physical and emotional challenges of hair loss.”
Frank Fazio, President and CEO of Amplifica Holdings Group
“Amplifica has built a proprietary portfolio of signaling molecules that regulate the hair follicle growth cycle, and this financing advances them further into clinical development.”
“Our discovery platform has yielded candidates that activate follicle regeneration through distinct, complementary mechanisms of action. Advancing multiple mechanisms in parallel maximizes our probability of clinical success and reinforces our leadership in hair regeneration for men and women.”
Wajdie Ahmad, Co-Founder and Executive Chairman of Amplifica Holdings Group
